Barclays PLC lifted its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 433.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 69,222 shares of the company’s stock after purchasing an additional 56,244 shares during the period. Barclays PLC’s holdings in Y-mAbs Therapeutics were worth $910,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp increased its position in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the period. Geode Capital Management LLC grew its position in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after acquiring an additional 47,846 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth $178,000. Finally, Squarepoint Ops LLC grew its position in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares during the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.
Y-mAbs Therapeutics Price Performance
Shares of YMAB stock opened at $6.33 on Wednesday. The business’s fifty day moving average price is $10.15 and its 200 day moving average price is $12.09. The firm has a market capitalization of $283.51 million, a PE ratio of -11.72 and a beta of 0.69. Y-mAbs Therapeutics, Inc. has a 1-year low of $6.01 and a 1-year high of $20.90.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Oppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $20.89.
Get Our Latest Report on Y-mAbs Therapeutics
Y-mAbs Therapeutics Profile
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Recommended Stories
- Five stocks we like better than Y-mAbs Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- 3 Healthcare Dividend Stocks to Buy
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report).
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.